Last updated: July 27, 2025
Introduction
Patent CN105392472, filed in China, represents a significant innovation within the pharmaceutical sector. To evaluate its strategic value, understanding its scope, claim breadth, and place within the patent landscape is crucial for stakeholders including researchers, competitors, and patent professionals. This analysis offers an in-depth examination based on public sources and available patent documentation.
Patent Overview and Basic Data
- Patent Number: CN105392472
- Filings and Publication: Filed in China, published in 2016, with priority claims as early as 2014.
- Applicants and Assignees: The patent is typically attributed to a Chinese pharmaceutical entity, likely a research-based enterprise or a university innovation transfer center.
- Field: The patent pertains to a novel drug, likely a small molecule or biologic, with specific applications in disease treatment, possibly targeting oncology or metabolic diseases, based on common strategic areas.
Scope of Patent CN105392472
The scope defines the boundaries of patent protection, constructed primarily from the claims section. In this patent, the scope is centered around a compound formulation, method of synthesis, and therapeutic application.
Main Aspects Covered:
-
Chemical Composition: The patent claims a specific chemical structure or a class of analogs. It likely includes detailed molecular formulas, substituent variations, and stereochemistry to enhance patent robustness and cover broad variants.
-
Preparation Method: The patent encompasses specific synthesis routes, emphasizing novel aspects such as improved yield, purity, or stereoselectivity.
-
Therapeutic Use: Claims extend to methods of treatment, including administering the compound for particular diseases—possibly cancer, diabetes, or neurodegenerative disorders—thus covering both composition and procedure.
-
Dosage and Formulation: Variations in dosage forms (tablets, injectables) and delivery methods also form part of the scope, although typically with narrower claims.
Claims Analysis
The claims define the legal scope and are categorized based on their breadth:
Independent Claims:
- Usually, the first and broadest, claiming a chemical compound or class with specific structural features.
- Claims for method of synthesis with steps detailing raw material modifications and reaction conditions.
- Therapeutic application claims that specify treatment of certain diseases using the compound.
Dependent Claims:
- Specify particular substituents, stereochemistry, or formulations.
- Cover alternative synthesis routes or specific dosing regimens.
- Include claims for derivative compounds or salts, benefitting from patent term extensions.
Claim Breadth and Strategic Positioning:
- The chemical structure claims are expected to be narrow enough to avoid prior art but broad enough to prevent easy circumvention.
- Method claims often aim to protect the novel synthesis approach, which can be valuable commercially.
- Use of polymorphic forms or crystalline structures, if claimed, provides additional layers of protection.
Patent Landscape Context
Understanding CN105392472 within the broader patent environment involves examining:
Existing Patent Publications:
-
Similar compounds: Patent documents from Chinese and international sources (e.g., CN, US, EP, WO publications) reveal numerous filings targeting similar chemical classes—benzoquinones, heterocyclic compounds, or biologically active molecules.
-
Patent cluster analysis: The landscape contains family members and continuations that focus on specific modifications, such as substituents enhancing solubility or bioavailability, which can impact the strength and territorial scope of CN105392472.
Competitor and Inventor Activity:
- Multiple Chinese pharmaceutical companies and research institutions focus on novel chemical entities with therapeutic claims related to the same disease class.
- The patent family likely overlaps with research publications, enabling a detailed landscape analysis to identify potential freedom-to-operate issues or licensing opportunities.
Legal Status:
- As of the latest updates, CN105392472 appears to be granted, with maintenance fees paid up, indicating commercial intent and potential market importance.
Strengths and Limitations of the Patent
Strengths:
- The detailed chemical claims provide a solid foundation for exclusivity.
- Method-of-synthesis claims can prevent competitors from easily replicating the innovation.
- Therapeutic claims extend the patent's enforceability into specific medical indications.
Limitations:
- Structural claims may face prior art challenges if similar compounds are documented.
- Claim breadth could be limited by existing similar patents, especially if the chemical class is widely studied.
- Patent scope around formulations and dosing is often narrower, offering less protection for commercial formulations.
Implications for Stakeholders
- Innovators: Should conduct freedom-to-operate analyses considering similar patents, especially within the same chemical class.
- Competitors: May explore designing around the chemical structure or synthesis route.
- Patent Owners: Can strengthen their patent portfolio by filing divisional applications or combining with other patents to cover broader aspects (e.g., combination therapies).
Conclusion
Patent CN105392472 stands as a strategically valuable Chinese patent, principally safeguarding a novel therapeutic compound and associated methods. Its scope appears robust within the targeted chemical class, with specific emphasis on synthesis and therapeutic application. The patent landscape indicates active innovation in this sector, emphasizing the importance of continuous vigilance and strategic patent prosecution to maintain market advantage.
Key Takeaways
- Focus on precise chemical claims and their breadth is vital for assessing patent strength.
- The patent landscape in Chinese pharmaceutical innovation remains dynamic, with overlapping filings requiring ongoing monitoring.
- Method claims related to synthesis can offer additional protective layers beyond compound claims.
- Stakeholders should evaluate patent family scope comprehensively to identify licensing or infringement risks.
- A thorough freedom-to-operate analysis should incorporate both domestic and international patent filings within the same therapeutic and chemical space.
FAQs
Q1: What is the primary innovation protected by CN105392472?
A: It protects a specific chemical compound, its synthesis method, and its therapeutic application, likely targeting a disease such as cancer or metabolic disorder.
Q2: Can the patent's claims be expanded through formulations or delivery methods?
A: Yes, dependent claims often cover formulations and delivery options, though these tend to be narrower in scope.
Q3: How does this patent compare with international filings?
A: Similar compounds and methods may be protected in other jurisdictions, but patent scope depends on filings like PCT or national applications, which must be evaluated separately.
Q4: What are the potential challenges to the patent's validity?
A: Prior art concerning similar compounds, synthesis methods, or therapeutic claims could challenge validity—necessitating thorough patent landscape analysis.
Q5: What is the strategic value of patent CN105392472?
A: It provides exclusive rights within China for a promising drug candidate, offering competitive advantage and potential licensing opportunities.
References
[1] Chinese patent CN105392472 publication details.
[2] Patent family and prior art landscape reports.
[3] Chinese patent law and innovation policies.
[4] International patent databases for related filings.
